More than half of people with a rare life-threatening bleeding condition received lasting relief from an experimental antibody treatment, clinical trial results show.

Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without serious bleeding episodes for at least a year, according to results published Dec. 9 in